Tecentriq Hybreza
- Product NDC
- 50242-933
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- atezolizumab and hyaluronidase-tqjs
- Dosage form
- INJECTION
- Route
- SUBCUTANEOUS
- Labeler
- Genentech, Inc.
- Application
- BLA761347
- Marketing category
- BLA
- Substance
- ATEZOLIZUMAB; HYALURONIDASE (HUMAN RECOMBINANT)
- Current FDA listing
- Yes
Packages
| Package NDC | Description | Marketing start | Marketing end | Sample | Status |
|---|
| 50242-933-86 | 1 VIAL, SINGLE-DOSE in 1 BOX (50242-933-86) / 15 mL in 1 VIAL, SINGLE-DOSE | 20240912 | | Yes | Historical |
Related DailyMed Labels
| Set ID | Title | Manufacturer | Effective date | Type | Version |
|---|
| a617b089-ce66-464b-987b-b45d029b4d6f | These highlights do not include all the information needed to use TECENTRIQ HYBREZA safely and effectively. See full prescribing information for TECENTRIQ HYBREZA. TECENTRIQ HYBREZA ® (atezolizumab and hyaluronidase-tqjs) injection, for subcutaneous use Initial U.S. Approval: 2024 | Genentech, Inc. | Roche Diagnostics GmbH | Genentech, Inc. (Oceanside) | F. Hoffmann-La Roche AG | 2026-05-20 | HUMAN PRESCRIPTION DRUG LABEL | 7 |
| a617b089-ce66-464b-987b-b45d029b4d6f | These highlights do not include all the information needed to use TECENTRIQ HYBREZA safely and effectively. See full prescribing information for TECENTRIQ HYBREZA. TECENTRIQ HYBREZA™ (atezolizumab and hyaluronidase-tqjs) injection, for subcutaneous use Initial U.S. Approval: 2024 | Genentech, Inc. | Roche Diagnostics GmbH | Genentech, Inc. (Oceanside) | F. Hoffmann-La Roche Ltd. | 2025-08-22 | HUMAN PRESCRIPTION DRUG LABEL | 3 |